chevron-orange.svg

Greater Accuracy With Less Ambiguity

Artificial Intelligence Meets Biology

Leveraging artificial intelligence-based technology, DecisionDx® DiffDx-Melanoma is an objective test with a high level of accuracy, low technical failure, low intermediate risk, and an inclusion of a variety of both benign nevi and malignant lesions.

  • 35

    Genes

Neural networks are used to identify 32 genes spanning a range of important biological processes, along with 3 control genes, to best classify melanocytic lesions.

  • 2

    Algorithms

Two proprietary algorithms are applied to the gene expression patterns to identify the malignant potential of a lesion.

  • 1

    Result

One clinically actionable result in over 96% of the cases including multiple types of benign nevi and malignant melanoma.

DiffDx-Melanoma Genes By Function

Protein Synthesis Tumorigenesis
*CST6 ABLIM1 *BAP1 ATP6V0E2 RPL37A ANXA8L1 *FXR1
CSTA DSP GATA3 DCT RPS16 BCL2A1 *HNRNPL
*CLCA2 KRT2 KLF5 GPR143 *BTG1 *YKT6
*GJA1 KRT17 *SAP130 PTN *CXCL14
HAL NES SFN WIPI1 DUSP4
*MGP *PPL TP63 *S100A8
*S100A9

*Genes also included in DecisionDx®-Melanoma assay.

WP Feedback

Dive straight into the feedback!
Login below and you can start commenting using your own user instantly

Scroll to Top